Evidence map›Paper›PMID 23893454›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2013

Animal models for dystonia.

Bethany K Wilson, Ellen J Hess

Abstract readReview
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Behavioral signature of trihexyphenidyl in theDystonia (Lausanne, Switzerland) · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. The pathogenesis of blepharospasm.Frontiers in neurology · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bethany K WilsonDepartment of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Ellen J Hess
Emory University · US

Funding

TRAINING IN SYSTEMS AND INTEGRATIVE BIOLOGY:NEUROSCIENCET32GM008605 · NIGMS · EMORY UNIVERSITY · PI SMITH, YOLAND · 1996 to 2015
$4.2M
Pathophysiology of dystonia: animal modelsR01NS033592 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HESS, ELLEN J. · 2001 to 2010
$3.5M
Cerebellar stimulation for the treatment of dystonia: preclinical studiesR21NS077905 · NINDS · EMORY UNIVERSITY · PI HESS, ELLEN J. · 2012 to 2013
$422k
Generation of a mouse model of L-DOPA-responsive dystonia (DRD)R21NS059645 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HESS, ELLEN J. · 2007 to 2008
$395k
NIGMS NIH HHS T32 GM008605NIGMS NIH HHS T32 GM8605NINDS NIH HHS R01 NS033592NINDS NIH HHS R01 NS33592NINDS NIH HHS R21 NS059645NINDS NIH HHS R21 NS077905
6 · The paper itself

Abstract

Symptomatic animal models have clinical features consistent with human disorders and are often used to identify the anatomical and physiological processes involved in the expression of symptoms and to experimentally demonstrate causality where it would be infeasible in the patient population. Rodent and primate models of dystonia have identified basal ganglia abnormalities, including alterations in striatal GABAergic (ie, transmitting or secreting γ-aminobutyric acid) and dopaminergic transmission. Symptomatic animal models have also established the critical role of the cerebellum in dystonia, particularly abnormal glutamate signaling and aberrant Purkinje cell activity. Further, experiments suggest that the basal ganglia and cerebellum are nodes in an integrated network that is dysfunctional in dystonia. The knowledge gained from experiments in symptomatic animal models may serve as the foundation for the development of novel therapeutic interventions to treat dystonia. © 2013 Movement Disorder Society.

Indexed as

Disease Models, AnimalDystoniaAnimalsAnimals, Genetically ModifiedBasal GangliaHumansNeurotransmitter AgentsNeurotransmitter Agentsbasal gangliacerebellummouse modelprimate model

Identifiers

PMID23893454
PMCPMC3728703
OpenAlexW1778164566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.